Kimberly-Clark (KMB) Barclays 18th Annual Americas Select Conference summary
Event summary combining transcript, slides, and related documents.
Barclays 18th Annual Americas Select Conference summary
5 May, 2026Strategic evolution and portfolio transformation
Executing a major strategic shift by reducing international consumer tissue exposure via a joint venture with Suzano and expanding into consumer health through the proposed Kenvue acquisition.
Powering Care strategy focuses on driving a virtuous cycle of growth through superior product innovation, cost efficiency, and enhanced global operating models.
Emphasis on serving all consumer segments, not just premium, by innovating across value tiers and addressing evolving consumer needs globally.
Joint venture with Suzano aims to stabilize margins and leverage complementary strengths in tissue and pulp production, with mechanisms for future exit and value realization.
Proceeds from the Suzano deal will help fund the Kenvue acquisition, maintaining balance sheet strength.
Financial performance and risk management
Achieved positive volume mix growth in North America and international personal care, outpacing industry trends.
Maintains discipline in managing commodity cost volatility, with hedging covering 80% of input costs and a toolkit developed from recent crises.
Projected $50 million in Q2 input cost inflation, with plans to fully mitigate as the year progresses; potential for higher costs if oil remains elevated.
Ongoing productivity gains (6% gross productivity in 2024 and 2025 Q1) and overhead savings support margin expansion.
Kenvue acquisition rationale and integration
Acquisition aims to create a global health and wellness leader, leveraging category growth tailwinds from aging populations and complementary geographic strengths.
Integration planning focuses on best talent from both organizations, with a leadership team selected through rigorous assessment.
Cost synergy target of $1.9 billion (13% of Kenvue 2025 sales) is supported by detailed workstreams and past execution in productivity, procurement, and marketing.
Portfolio management will remain disciplined, with ongoing evaluation of underperforming brands and potential divestitures.
Latest events from Kimberly-Clark
- Q1 2026 delivered 2.7% sales growth and strong profit, with transformation and acquisitions progressing.KMB
Q1 2026 Prepared Remarks28 Apr 2026 - Q1 2026 delivered 2.7% sales growth and 2.1% adjusted EPS growth, with a strong 2026 outlook.KMB
Q1 2026 (Q&A)28 Apr 2026 - Innovation and acquisitions drive growth, margin expansion, and strong EPS outlook.KMB
Q4 2025 Prepared Remarks11 Apr 2026 - Board recommends director elections, auditor ratification, say-on-pay, and opposes independent chair proposal.KMB
Proxy filing23 Mar 2026 - Shareholders will vote on directors, executive pay, and auditor ratification at the annual meeting.KMB
Proxy filing23 Mar 2026 - Transformation, innovation, and Kenvue integration drive global growth and value creation.KMB
Consumer Analyst Group of New York Conference (CAGNY) 202619 Feb 2026 - Issuance of common stock for a merger was approved; final results to be filed with the SEC.KMB
AGM 20263 Feb 2026 - Q2 profit and EPS surged on organic growth, innovation, and raised full-year outlook.KMB
Q2 2024 Prepared Remarks3 Feb 2026 - Q2 organic sales up 5% and adjusted EPS up 19%-20%, with 2024 outlook raised.KMB
Q2 2024 (Q&A)3 Feb 2026